It's odd to not include the control arms for sure OTOH on a none or mild endpoint they did show 6 months duration (surprisingly). However I do find it odd that the duration on this (more appropriate) endpoint is no different than the 1-point improvement on the GLS scale which was identical - i.e. there were minimal to no patients who had a 1-point improvement from baseline of 3 to 2 everyone who started at 3 seemed to go to 0 or 1 when the effects started to wear off. You can easily see this if the interval between visits is very long and then you can easily miss the time points when efficacy gradually goes from baseline of 3 to 2 to 0/1 (non/mild) so somewhat weird data. Here's hoping the 6 month duration on non-mild w reasonable AE profile doesn't hold up
ah okay I stand corrected - thsi makes alot more sense and is c/w the PR my apples to apples of 26 week vs 36 weeks for daxi on the 1 point stands and I am not worried then in the least by this data (in fact it reinforces that doubling the dose doesn't reach the efficacy bar of daxi and w daxi you can get longer duration on half the toxin exposure vs jeauveauxx or botox
News 
Market Data 
Discover 
